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The binding of small molecules to distinctive three-dimensional
structures in mRNA provides a new dimension in RNA control,
previously limited to the targeting of secondary structures with
antisense and RNA interference; such targeting can modulate
mRNA function and rates of protein biosynthesis. Small molecules
that selectively bind the iron-responsive element (IRE), a specific
three-dimensional structure in the noncoding region of the ferritin
mRNA model that is recognized by the iron-regulatory protein
repressor, were identified by using chemical footprinting. The
assay used involved an oxoruthenium(IV) complex that oxidizes
guanine bases in RNA sequences. Small molecules that blocked
oxidation of guanines in the internal loop region were expected to
selectively increase the rate of ferritin synthesis, because the
internal loop region of the ferritin IRE is distinctive from those of
other IREs. The natural product yohimbine was found (based on gel
mobility shifts) to block cleavage of the internal loop RNA site by
>50% and seemed to inhibit protein binding. In the presence of
yohimbine, the rate of biosynthesis of ferritin in a cell-free expres-
sion system (rabbit reticulocyte lysate) increased by 40%. Assign-
ment of the IRE–yohimbine interaction as the origin of this effect
was supported by a similar increase in synthesis of luciferase
protein in a chimera of the IRE and luciferase gene. The identifi-
cation of a small, drug-like molecule that recognizes a naturally
occurring three-dimensional mRNA structure and regulates protein
biosynthesis rates raises the possibility that small molecules can
regulate protein biosynthesis by selectively binding to mRNA.
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The targeting of small molecules to three-dimensional struc-tures in RNA has the potential to change the synthesis rate
of the encoded proteins (1–4); an example is alteration of the
control of reverse-transcription rate rates of HIV-1 RNA by
trans-activation responsive region RNA, a target of many drug-
like molecules (5–9). A principal challenge in targeting mRNA
is identifying three-dimensional RNA structures that are func-
tionally relevant and exhibit structures amenable to selective
binding in the presence of large quantities of other nucleic acids
(5–7). Recent findings on the activation of bacterial riboswitches
by metabolites provide incentive to pursue mRNA binding as a
new avenue for pharmaceutical research (10), particularly given
the intriguing possibility that such elements exist in eukaryotes
(11, 12). The advantages of using drug-like molecules to target
three-dimensional RNA targets include the ability to escape
biological systems that respond to targeting helical RNA struc-
tures (13), the ability to identify potentially useful RNA targets
in genome sequences (14, 15), and the possibility of synthesizing
reasonably large quantities of RNA for screening by chemical
methods (2, 16). An additional appeal is that chemical-
footprinting techniques, which are currently more effective for
nucleic acids than proteins, allow for determining the precise site
of binding of a small molecule on an RNA target by using routine
sequencing methods on small quantities of material (17–19). We
demonstrate here that such a chemical-footprinting technique
can be used to identify a drug-like, RNA-binding molecule that
is selective for a physiologically relevant site in mRNA and
induces a change in the synthesis rate of the encoded protein.
There have been a limited number of reported ligand–RNA
interactions that affect protein synthesis (20–22). Werstuck and
Green (20) described such a system in which RNA aptamers
selected for aminoglycoside antibiotics were inserted within the
5 untranslated region (UTR) of a gene; subsequent translation
in the presence of the selected antibiotic showed a dose-
dependent inhibitory effect on translation of protein both in vitro
and in living cells. In addition, it has been reported that forcing
a nonphysiologically relevant RNA–protein interaction in the 5
UTR of a gene by using a secondary ligand–RNA interaction can
diminish protein synthesis dramatically (22). Another study
identified an intercalator that targeted the hepatitis C virus
internal ribosome-entry site to repress protein synthesis (21). To
date, we are not aware of a system wherein an RNA–ligand
interaction was used to increase the synthesis rate of an encoded
protein.
A family of related, folded, stem-loop structures in mRNAs
called iron-responsive elements (IREs; Fig. 1) coordinate the
synthesis of proteins required for iron homeostasis (23, 24).
Protein repressors called iron-regulatory proteins (IRPs) selec-
tively recognize the IRE RNA structures and prevent protein
synthesis by inhibiting ribosome binding (25–27). The ferritin
IRE RNA folded in vivo has the same structure as in vitro, based
on results with chemical nuclease probes for three-dimensional
RNA structure protein in cultured mammalian cells (28). At
normal cell iron concentrations, the ferritin mRNA is repressed
by IRP binding but is activated when iron concentrations in-
crease through changes in the IRE–IRP complex (17). Physio-
logically, such a situation occurs when genetic diseases such as
sickle cell disease are treated with regular blood transfusions,
leading to iron overload and saturation of available ferritin with
iron (17); excess iron then has to be removed by cumbersome
chelation therapies. Because only 50% of the ferritin mRNA
is activated (29, 30), a strategy for increasing ferritin synthesis is
finding a small molecule that binds to the ferritin IRE, blocks or
alters binding of the IRP, and allows translation of the ferritin
mRNA (3). A challenge in such a strategy is identifying a small
molecule that selectively interacts with the ferritin IRE com-
pared to mRNA with other IRE isoforms, such as the transferrin
receptor (TfR) IRE. Members of the IRE family share the
hairpin loop structure but vary in the structure of the helical
stem. The ferritin IRE has a distinctive internal loop structure
(U6-C8 with a G7-C25 base pair) that is absent in other IRE
isoforms (31–34). Therefore, compounds that bind to the inter-
nal loop of the ferritin IRE should be selective for the ferritin
mRNA over other IREs.
A number of chemical reagents have been used to oxidize and
cleave RNA, which revealed a variety of structural features and
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interactions (17–19). We have focused on complexes based on
Ru(tpy)(bpy)O2 (tpy, 2,2,2-terpyridine; bpy, 2,2-bipyridine),
which oxidizes guanines in RNA based on their solvent acces-
sibility (35, 36). Reaction of the ferritin IRE with Ru(tpy)(bpy)O2
produces cleavage at guanine with intensities that track the
solvent accessibilities determined from NMR structures (16, 37).
Based on the differences in structures for the ferritin and TfR
IREs, we reasoned that small molecules that blocked sites in the
region of the ferritin internal loop (i.e., G23, G26, G27) but not
guanines in the hairpin loop (i.e., G16, G18) would be promising
candidates for selective binding to the ferritin IRE. In this
article, a small molecule that blocks oxidation of guanines by
Ru(tpy)(bpy)O2 adjacent to the internal loop is shown to bind
to the IRE and change or disrupt the IRE–IRP complex to
increase the rate of ferritin synthesis in cell-free extracts.
Materials and Methods
Cloning, Transcription, and Ru(tpy)(bpy)O2 Assay. Desired se-
quences along with the T7 promoter sequence were cloned by
PCR into pUC19K vectors. Plasmids were digested with a
restriction enzyme to allow for run-off transcription by using a
MEGAshortscript T7 Kit (Ambion, Austin, TX). RNA was
3-end-labeled with 5-[32P]pCp (PerkinElmer) by using T4 RNA
ligase overnight at 4°C (38). Ru-OH2 was synthesized according
to published procedures (39). The RuO2 oxidant was generated
by bulk electrolysis, holding the aqueous solution at 0.85 V for
10 min. [32P]RNA was folded (40 mM Tris100 mM KCl, pH 7.2)
by heating to 95°C for 5 min followed by slow cooling to room
temperature. [32P]RNA and yohimbine HCL (Sigma) were
incubated at room temperature for 15 min; RuO2 (100 M) was
added and reacted for 5 min. The reaction was quenched with
ethanol, speed-vacuumed to dryness, aniline-treated, and
washed twice with water. Samples were separated on 20% (7 M
urea) denaturing gels, which then were exposed to a phos-
phorimaging screen overnight and analyzed by using a phosphor-
imager. Bands were quantitated by using IMAGEQUANT software.
Gel Mobility-Shift Assay. [32P]RNA was folded (10 mM Hepes40
mM KCl, pH 7.2); 5 l of folded [32P]RNA, binding buffer (10
mM Hepes40 mM KCl0.3% Nonidet P-405% glycerol3 mM
MgCl2), yohimbine, and heparin (5 mgml) were incubated at
30°C for 20 min. Human IRP1 (65 nM; MBI Fermentas,
Amherst, NY) and DTT (1 mM) were added, and incubation
continued at 37°C for 20 min. The reaction was terminated by the
addition of 80% glycerolbromophenol blue dye. RNA–protein
complexes were separated on 6% nondenaturing gels (29:1
acrylamidebisacrylamide) at 4°C. Gels were dried and phos-
phorimaged. Bands were quantitated by using IMAGEQUANT
software. For shift assays on full-length mRNA, the conditions
were the same as described above with the following exceptions:
[-32P]UTP was added to the transcription reaction as a trace
label, 220 nM RNA and 660 nM IRP1 or IRP2 was used, and 4%
nondenaturing gels were run for at least 16 h. For these studies,
the human IRP1 and IRP2 used were isolated as described by
Allerson et al. (40).
Small-Molecule Translation Assay. Full-length human ferritin
mRNA (human H-chain; the 5 UTR is 268 bases and contains
the IRE) was transcribed from a linearized pCRII-TOPO vector
by using the SP6 promoter. For the G18A ferritin mutant,
site-directed mutagenesis was performed on the human ferritin
sequence [from pCRII-TOPO vector, subcloned into pBlue-
script IISK()] by using a QuikChange mutagenesis kit (Strat-
agene), and RNA was transcribed from the linearized vector by
using the T7 promoter. For IRE-luc, a 1,739-bp fragment
containing the gene coding for Luciferase from a pGEM-luc
vector (Promega) was amplified by PCR and blunt-end ligated
into a vector containing the human IRE sequence. The resulting
plasmid contained the IRE 18 bases upstream of the luciferase
start codon, and RNA was synthesized off of the T7 promotor.
Translation of mRNA (133 nM), after preincubation with or
without yohimbine for 20 min at 30°C, used reticulocyte lysates
(Promega) and [35S]methionine (PerkinElmer; final volume, 25
l) incubated at 30°C for 15 min. Newly synthesized protein was
analyzed by electrophoresis on 16% polyacrylamide gels in
Tris-glycine SDS buffer (pH 8.3), which was run for 1.75 h, fixed
in 50% methanol7% acetic acid for 10 min, dried, and exposed
to a phosphorimaging screen overnight. Protein bands (based on
incorporation of [35S]methionine) were quantitated by using
IMAGEQUANT software.
Fluorescence Binding Assay. Steady-state fluorescence measure-
ments were performed on a Cary Eclipse fluorimeter (Varian).
All measurements were made at room temperature in 50 mM
Tris (pH 7.4)100 mM NaCl1 mM MgCl2 on RNA that had
been melted and reannealed. The excitation wavelength was 290
nm, and the emission wavelength was 359 nm. The Kd of the
yohimbine–RNA complex was calculated by curve fitting of the
fluorescence intensity as a function of [RNA] at a concentration
of 10 M yohimbine by using the following equation (assuming
1:1 binding):
Y  A1RNAKd  1 , [1]
where A is the difference in fluorescence intensity at 0 M RNA
and an infinite RNA concentration. Binding assays were re-
peated at least three times on two different preparations of
RNA.
Results
Identification of IRE Ligands. Several commercially available small
molecules have been studied for binding to RNA (6, 41). A
subset of these molecules was selected and screened for
selective binding near the internal loop IRE, as revealed by
oxidation with Ru(tpy)(bpy)O2. We primarily focused on
compounds based on the parent structures of indole, phe-
nothiazine, and diazepam. In this experiment, radiolabeled
IRE oligoribonucleotide (50-mer) was subjected to oxidation
with Ru(tpy)(bpy)O2 in the presence of increasing amounts
Fig. 1. RNA secondary structures of human ferritin IRE, mutant TfR IRE, and
the structure of the small molecule yohimbine.
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of the selected small molecule. The majority of the compounds
screened blocked oxidation of G16 but did not affect oxidation
of the guanines in the region of the internal loop. One
compound, the natural product yohimbine (42) (Fig. 1) selec-
tively inhibited cleavage at G23 and G27 by 	50% with little
effect on G16 (Fig. 2), indicating selective binding of yohimbine
in the region of the ferritin IRE-specific internal loop. The
internal loop region confers selectivity to IRP binding among
IRE isoforms (3). NMR studies on ferritin IRE structures used
either the frog ferritin IRE sequence (33), which has the same
internal loop sequence as the human L-ferritin, or a consensus
sequence that has a C bulge, rather than the internal loop (34);
the results were very similar except for the size of the helix
distortion. In the human ferritin-H IRE used here (Fig. 1),
which differs from human ferritin-L and frog ferritin IRE only
by having a C-G closing base pair rather than a U-G, the G26
residue, also in the internal loop region of the IRE, was not
protected by yohimbine from oxidation. This result is consis-
tent with the observation that G26 and G27 exhibit different
environments when probed by NMR and metal-binding
studies (43).
The native fluorescence of yohimbine was also used to study
binding to the IRE. Titration of yohimbine with increasing
quantities of IRE quenched the yohimbine fluorescence, and
subsequent fitting of the emission profile, gave a binding con-
stant of 3.9 
 1.2 M. The affinity is comparable in magnitude
to values determined for a number of RNA–ligand interactions
identified by systematic evolution of ligands by exponential
enrichment (SELEX) (44, 45) and reflects the overall binding of
yohimbine to the RNA, not necessarily that for the specific
internal loop site. Although the data fit well for the formation of
a 1:1 yohimbine–RNA complex, the binding of a second yohim-
bine cannot be completely excluded.
The effect of yohimbine binding to the ferritin IRE was also
analyzed as the shift in electrophoretic mobility by using radio-
labeled IRE and the IRP. Addition of yohimbine to the ferritin
IRE inhibited formation of the IRE–IRP complex and concom-
itantly increased the quantity of free RNA (Fig. 3). As shown in
Fig. 3, the increase in the quantity of free RNA was 8.0 
 2.7%
in the presence of 40 M yohimbine. Given the dissociation
constant of the IRE–IRP interaction of 90 pM (46) and the
concentrations of IRP and yohimbine, the calculated displace-
ment is 8%, which is in good agreement with the observed
displacement.
Selectivity of the yohimbine–ferritin IRE interactions was
evaluated by comparing the interaction of yohimbine with
ferritin to an IRE isoform, a single TfR IRE (Fig. 1), which has
a C bulge instead on an internal loop using Ru(tpy)(bpy)O2
oxidation as a probe. The G selectivity of the probe and the
decrease in potential sites caused by the relatively A-U-rich base
pairing in TfR-IRE helices, required conversion of a G-C base
pair to a G-U base pair (C24 3 U24 substitution) (Fig. 1) to
provide a reporter near the C bulge. The mutation did not alter
the predicted folding of the structure as determined by MFOLD
analysis (47, 48). When the mutant TfR IRE was oxidized by
Ru(tpy)(bpy)O2 with increasing amounts of yohimbine, oxida-
tion at G16 was inhibited but the guanines near the C bulge were
not blocked (Fig. 4), in contrast to the ferritin IRE, which
emphasizes the selectivity of yohimbine binding to the ferritin
IRE. The dissociation constants of yohimbine for both the native
TfR IRE and the mutant were detectably weaker than that for
the ferritin IRE by fluorescence titration (see supporting infor-
Fig. 2. Effect of yohimbine on guanine oxidation in human IRE RNA. (Left)
Lanes 1–6, [RuO2]  100 M. [yohimbine]: lane 1, 0 M; lane 2, 1 M; lane 3,
5 M; lane 4, 10 M; lane 5, 20 M; lane 6, aniline-treated control; lane 7, RNA
only control. (Right) Quantitations of [32P]RNA bands. Cleavage intensity is in
arbitrary units normalized to cleavage at G0.
Fig. 3. Gel mobility-shift assay. (Left) Upper band is the shifted ferritin IRE
RNA–IRP1 complex, and the lower band is unshifted RNA. [IRP1]  65 nM;
[RNA]  32.5 nM. [yohimbine]: lane 1, 0 M; lane 2, 10 M; lane 3, 20 M; lane
4, 40 M; lane 5, 0 M, no IRP1. (Right) Quantitations of [32P]RNA bands.
Legend values indicate the final concentration of yohimbine in the assay.
Fig. 4. Effect of yohimbine on guanine oxidation in the C243U24 mutant TfR
IRE. (Left) Lanes 1–6, [RuO2]  100 M. [yohimbine]: Lane 1, 0 M; lane 2, 1
M; lane 3, 5 M; lane 4, 10 M; lane 5, 20 M; lane 6, 40 M; lane 7, RNA-only
control; lane 8, aniline-treated control. (Right) Quantitations of [32P]RNA
bands. Cleavage intensity is in arbitrary units normalized to the intensity at G0.













mation, which is published on the PNAS web site). Another
measure of the selectivity of the yohimbine–ferritin IRE inter-
action is the fact that the majority of the other compounds tested
with the ferritin IRE gave results similar to those of the
yohimbine–TfR IRE interaction.
Acceleration of Ferritin Synthesis by Yohimbine. To determine
whether binding of yohimbine to the internal loop of the ferritin
IRE would increase the rate of ferritin translation, we analyzed
ferritin synthesis directed by full-length ferritin mRNA in a eukary-
otic cell-free expression system, generated by lysing rabbit reticu-
locytes. Addition of yohimbine to ferritin mRNA before translation
increased ferritin synthesis by 	40% (Fig. 5). In contrast, addition
of Hoechst 33258, which is well known to bind nucleic acids (49),
inhibited ferritin synthesis by 	50% (data not shown). As shown in
this (see supporting information) and earlier work (16, 43), a G18A
mutation in the ferritin IRE (G18 forms a base pair with C14 in the
IRE terminal loop) (33, 34) displays a reduced affinity for IRP (16,
43), which increases ferritin mRNA translation. Translation of
mRNA with the G18A mutation in the IRE was unaffected by
yohimbine (Fig. 5), again indicating the selectivity of the yohimbine
effect for the native ferritin-IRE structure.
To rule out any possible contributions of the mRNA coding
sequence on yohimbine-enhanced ferritin mRNA translation,
the ferritin IRE was cloned upstream of the sequence coding for
the luciferase protein (IRE-luc). The chimeric mRNA was
shown to bind both IRP1 and IRP2; luciferase synthesis directed
by the IRE-luciferase chimeric mRNA was repressed compara-
bly to ferritin (see supporting information). Addition of yohim-
bine to IRE-luc produced a similar effect to ferritin with an
increase of 	40% in the levels of luciferase synthesis (Fig. 5).
Taken together, these data indicate that yohimbine selectively
alters mRNA repression by the ferritin IRE–IRP interaction.
Discussion
The three conclusions to be drawn from these experiments are
that (i) differential binding of small molecules to specific sites in
mRNA can be identified through chemical oxidation reactions,
and the targeting apparent in the footprinting experiment is
confirmed through examining alternative sequences and com-
pounds and by comparison of dissociation constants; (ii) differ-
ential binding of small molecules to specific three-dimensional
structures in mRNA can alter mRNA translation in a cell-free
expression system; and (iii) small molecules can effectively
distinguish between the different members of the IRE family of
regulatory structures to enhance RNA function. These strategies
should prove useful in developing therapeutic approaches to
increasing iron-storage capacity during iron overload and to
targeting related mRNA elements.
When yohimbine selectively bound the internal loop of the
ferritin IRE, the IREIRP repression was changed as indi-
cated by up-regulation of ferritin mRNA (Fig. 5). The increase
in translation could result simply from the increase in free
RNA generated by yohimbine binding, as seen in the gel-shift
assay. However, the 40% increase in synthesized protein is
greater than what would be expected solely from free RNA,
because the ferritin mRNA (133 nM) saturates the endogenous
IRP (9–12 nM) (50) in the cell-free expression system. The
yohimbine effect, therefore, is more than simply displacing the
IRP. One explanation could be that unwinding of the IRE
structure by yohimbine is more complete than by endogenous
initiation factors, a conjecture supported by the observations
that during iron overload, when the IRP is presumed to be
displaced (51), 40–50% of endogenous ferritin mRNA remains
untranslated (52, 53). The complexity of the interactions
among the IRE RNA, IRP repressor, and initiation factor
proteins is illustrated by the binding of the IRP repressor to
both the IRE and the large initiation scaffold protein, eIF-4G
(54). It likely is a combination of decreased IRP binding
coupled with unwinding of the IRE structure by yohimbine
that results in the increased protein-synthesis levels observed.
Positive regulation of mRNA translation by a small mole-
cule, illustrated here for the binding of yohimbine to a natural
RNA helix distortion in the ferritin IRE, is an example of a
process that can find use where increased synthesis would be
efficacious. Earlier examples of small molecules that altered
translation acted through dimerization (22) or intercalation
(21) and inhibited translation. In addition, until now, manip-
ulating mRNA function with small molecules has relied on in
vitro aptamer selection of the RNA followed by insertion of the
aptamer into the UTR of mRNA (20, 22) or the use of
engineered RNA–protein interactions to control protein syn-
thesis (22). The demonstration that natural, noncoding RNA
regulatory structures in mRNAs for normal proteins such as
ferritin can be recognized and targeted by small molecules
indicates the importance of searching for other targets in
mRNAs encoding proteins in which increased synthesis is
needed (e.g., in insulin deficiency).
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